nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydralazine—CYP3A4—Tamoxifen—pancreatic cancer	0.0176	0.24	CbGbCtD
Hydralazine—CYP3A4—Erlotinib—pancreatic cancer	0.0149	0.204	CbGbCtD
Hydralazine—CYP3A4—Irinotecan—pancreatic cancer	0.0135	0.185	CbGbCtD
Hydralazine—CYP3A4—Docetaxel—pancreatic cancer	0.00989	0.135	CbGbCtD
Hydralazine—CYP3A4—Sunitinib—pancreatic cancer	0.00985	0.135	CbGbCtD
Hydralazine—CYP3A4—Doxorubicin—pancreatic cancer	0.00737	0.101	CbGbCtD
Hydralazine—Dyspepsia—Sunitinib—pancreatic cancer	0.00201	0.00217	CcSEcCtD
Hydralazine—Leukopenia—Gemcitabine—pancreatic cancer	0.00201	0.00217	CcSEcCtD
Hydralazine—Neuropathy peripheral—Docetaxel—pancreatic cancer	0.002	0.00216	CcSEcCtD
Hydralazine—Vascular purpura—Epirubicin—pancreatic cancer	0.00199	0.00215	CcSEcCtD
Hydralazine—Jaundice—Docetaxel—pancreatic cancer	0.00199	0.00214	CcSEcCtD
Hydralazine—Decreased appetite—Sunitinib—pancreatic cancer	0.00198	0.00214	CcSEcCtD
Hydralazine—Conjunctivitis—Docetaxel—pancreatic cancer	0.00198	0.00214	CcSEcCtD
Hydralazine—Leukopenia—Fluorouracil—pancreatic cancer	0.00197	0.00213	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00197	0.00213	CcSEcCtD
Hydralazine—Cardiac failure congestive—Epirubicin—pancreatic cancer	0.00197	0.00212	CcSEcCtD
Hydralazine—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00196	0.00212	CcSEcCtD
Hydralazine—Constipation—Sunitinib—pancreatic cancer	0.00195	0.00211	CcSEcCtD
Hydralazine—Discomfort—Irinotecan—pancreatic cancer	0.00194	0.00209	CcSEcCtD
Hydralazine—Lymphadenopathy—Doxorubicin—pancreatic cancer	0.00193	0.00209	CcSEcCtD
Hydralazine—Renal failure acute—Epirubicin—pancreatic cancer	0.00193	0.00208	CcSEcCtD
Hydralazine—Arthralgia—Gemcitabine—pancreatic cancer	0.00191	0.00206	CcSEcCtD
Hydralazine—Myalgia—Gemcitabine—pancreatic cancer	0.00191	0.00206	CcSEcCtD
Hydralazine—Agranulocytosis—Docetaxel—pancreatic cancer	0.0019	0.00205	CcSEcCtD
Hydralazine—Hepatic function abnormal—Doxorubicin—pancreatic cancer	0.00189	0.00204	CcSEcCtD
Hydralazine—Discomfort—Gemcitabine—pancreatic cancer	0.00189	0.00204	CcSEcCtD
Hydralazine—Pruritus—Tamoxifen—pancreatic cancer	0.00189	0.00203	CcSEcCtD
Hydralazine—Oedema—Irinotecan—pancreatic cancer	0.00188	0.00203	CcSEcCtD
Hydralazine—Myalgia—Fluorouracil—pancreatic cancer	0.00188	0.00203	CcSEcCtD
Hydralazine—Pruritus—Erlotinib—pancreatic cancer	0.00187	0.00201	CcSEcCtD
Hydralazine—Discomfort—Fluorouracil—pancreatic cancer	0.00186	0.002	CcSEcCtD
Hydralazine—Purpura—Epirubicin—pancreatic cancer	0.00185	0.002	CcSEcCtD
Hydralazine—Vascular purpura—Doxorubicin—pancreatic cancer	0.00184	0.00199	CcSEcCtD
Hydralazine—Thrombocytopenia—Irinotecan—pancreatic cancer	0.00184	0.00199	CcSEcCtD
Hydralazine—Oedema—Gemcitabine—pancreatic cancer	0.00183	0.00198	CcSEcCtD
Hydralazine—Hepatitis—Docetaxel—pancreatic cancer	0.00183	0.00197	CcSEcCtD
Hydralazine—Cardiac failure—Epirubicin—pancreatic cancer	0.00183	0.00197	CcSEcCtD
Hydralazine—Diarrhoea—Tamoxifen—pancreatic cancer	0.00182	0.00197	CcSEcCtD
Hydralazine—Hypoaesthesia—Docetaxel—pancreatic cancer	0.00182	0.00196	CcSEcCtD
Hydralazine—Cardiac failure congestive—Doxorubicin—pancreatic cancer	0.00182	0.00196	CcSEcCtD
Hydralazine—Body temperature increased—Sunitinib—pancreatic cancer	0.0018	0.00195	CcSEcCtD
Hydralazine—Diarrhoea—Erlotinib—pancreatic cancer	0.0018	0.00195	CcSEcCtD
Hydralazine—Oedema—Fluorouracil—pancreatic cancer	0.0018	0.00194	CcSEcCtD
Hydralazine—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.00179	0.00193	CcSEcCtD
Hydralazine—Anorexia—Irinotecan—pancreatic cancer	0.00179	0.00193	CcSEcCtD
Hydralazine—Renal failure acute—Doxorubicin—pancreatic cancer	0.00179	0.00193	CcSEcCtD
Hydralazine—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.00176	0.0019	CcSEcCtD
Hydralazine—Dizziness—Tamoxifen—pancreatic cancer	0.00176	0.0019	CcSEcCtD
Hydralazine—Tachycardia—Fluorouracil—pancreatic cancer	0.00176	0.0019	CcSEcCtD
Hydralazine—Hypotension—Irinotecan—pancreatic cancer	0.00176	0.0019	CcSEcCtD
Hydralazine—Anorexia—Gemcitabine—pancreatic cancer	0.00175	0.00188	CcSEcCtD
Hydralazine—Dizziness—Erlotinib—pancreatic cancer	0.00174	0.00188	CcSEcCtD
Hydralazine—Anorexia—Fluorouracil—pancreatic cancer	0.00172	0.00185	CcSEcCtD
Hydralazine—Purpura—Doxorubicin—pancreatic cancer	0.00171	0.00185	CcSEcCtD
Hydralazine—Hypotension—Gemcitabine—pancreatic cancer	0.00171	0.00185	CcSEcCtD
Hydralazine—Flushing—Docetaxel—pancreatic cancer	0.0017	0.00183	CcSEcCtD
Hydralazine—Vomiting—Tamoxifen—pancreatic cancer	0.00169	0.00183	CcSEcCtD
Hydralazine—Cardiac failure—Doxorubicin—pancreatic cancer	0.00169	0.00182	CcSEcCtD
Hydralazine—Paraesthesia—Irinotecan—pancreatic cancer	0.00169	0.00182	CcSEcCtD
Hydralazine—Hypotension—Fluorouracil—pancreatic cancer	0.00168	0.00182	CcSEcCtD
Hydralazine—Hypersensitivity—Sunitinib—pancreatic cancer	0.00168	0.00181	CcSEcCtD
Hydralazine—Rash—Tamoxifen—pancreatic cancer	0.00168	0.00181	CcSEcCtD
Hydralazine—Dermatitis—Tamoxifen—pancreatic cancer	0.00168	0.00181	CcSEcCtD
Hydralazine—Vomiting—Erlotinib—pancreatic cancer	0.00168	0.00181	CcSEcCtD
Hydralazine—Dyspnoea—Irinotecan—pancreatic cancer	0.00168	0.00181	CcSEcCtD
Hydralazine—Headache—Tamoxifen—pancreatic cancer	0.00167	0.0018	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.00167	0.0018	CcSEcCtD
Hydralazine—Rash—Erlotinib—pancreatic cancer	0.00166	0.00179	CcSEcCtD
Hydralazine—Dermatitis—Erlotinib—pancreatic cancer	0.00166	0.00179	CcSEcCtD
Hydralazine—Dyspepsia—Irinotecan—pancreatic cancer	0.00166	0.00179	CcSEcCtD
Hydralazine—Headache—Erlotinib—pancreatic cancer	0.00165	0.00178	CcSEcCtD
Hydralazine—Paraesthesia—Gemcitabine—pancreatic cancer	0.00164	0.00177	CcSEcCtD
Hydralazine—Chills—Docetaxel—pancreatic cancer	0.00164	0.00177	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.00164	0.00177	CcSEcCtD
Hydralazine—Decreased appetite—Irinotecan—pancreatic cancer	0.00163	0.00176	CcSEcCtD
Hydralazine—Dyspnoea—Gemcitabine—pancreatic cancer	0.00163	0.00176	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00162	0.00175	CcSEcCtD
Hydralazine—Paraesthesia—Fluorouracil—pancreatic cancer	0.00162	0.00174	CcSEcCtD
Hydralazine—Pruritus—Sunitinib—pancreatic cancer	0.00161	0.00174	CcSEcCtD
Hydralazine—Constipation—Irinotecan—pancreatic cancer	0.00161	0.00173	CcSEcCtD
Hydralazine—Dyspnoea—Fluorouracil—pancreatic cancer	0.00161	0.00173	CcSEcCtD
Hydralazine—Decreased appetite—Gemcitabine—pancreatic cancer	0.00159	0.00172	CcSEcCtD
Hydralazine—Dyspepsia—Fluorouracil—pancreatic cancer	0.00159	0.00171	CcSEcCtD
Hydralazine—Nausea—Tamoxifen—pancreatic cancer	0.00158	0.00171	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00158	0.00171	CcSEcCtD
Hydralazine—Constipation—Gemcitabine—pancreatic cancer	0.00157	0.00169	CcSEcCtD
Hydralazine—Nausea—Erlotinib—pancreatic cancer	0.00157	0.00169	CcSEcCtD
Hydralazine—Decreased appetite—Fluorouracil—pancreatic cancer	0.00157	0.00169	CcSEcCtD
Hydralazine—Diarrhoea—Sunitinib—pancreatic cancer	0.00156	0.00168	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00155	0.00168	CcSEcCtD
Hydralazine—Feeling abnormal—Irinotecan—pancreatic cancer	0.00155	0.00167	CcSEcCtD
Hydralazine—Muscle spasms—Docetaxel—pancreatic cancer	0.00153	0.00165	CcSEcCtD
Hydralazine—Eosinophilia—Epirubicin—pancreatic cancer	0.00153	0.00165	CcSEcCtD
Hydralazine—Dizziness—Sunitinib—pancreatic cancer	0.00151	0.00163	CcSEcCtD
Hydralazine—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00151	0.00163	CcSEcCtD
Hydralazine—Angina pectoris—Epirubicin—pancreatic cancer	0.0015	0.00162	CcSEcCtD
Hydralazine—Body temperature increased—Irinotecan—pancreatic cancer	0.00149	0.0016	CcSEcCtD
Hydralazine—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00148	0.0016	CcSEcCtD
Hydralazine—Anaemia—Docetaxel—pancreatic cancer	0.00147	0.00159	CcSEcCtD
Hydralazine—Pancytopenia—Epirubicin—pancreatic cancer	0.00146	0.00158	CcSEcCtD
Hydralazine—Vomiting—Sunitinib—pancreatic cancer	0.00145	0.00157	CcSEcCtD
Hydralazine—Body temperature increased—Gemcitabine—pancreatic cancer	0.00145	0.00156	CcSEcCtD
Hydralazine—Dysuria—Epirubicin—pancreatic cancer	0.00144	0.00156	CcSEcCtD
Hydralazine—Neutropenia—Epirubicin—pancreatic cancer	0.00144	0.00156	CcSEcCtD
Hydralazine—Rash—Sunitinib—pancreatic cancer	0.00144	0.00155	CcSEcCtD
Hydralazine—Dermatitis—Sunitinib—pancreatic cancer	0.00144	0.00155	CcSEcCtD
Hydralazine—Urticaria—Fluorouracil—pancreatic cancer	0.00143	0.00154	CcSEcCtD
Hydralazine—Headache—Sunitinib—pancreatic cancer	0.00143	0.00154	CcSEcCtD
Hydralazine—Leukopenia—Docetaxel—pancreatic cancer	0.00143	0.00154	CcSEcCtD
Hydralazine—Body temperature increased—Fluorouracil—pancreatic cancer	0.00142	0.00154	CcSEcCtD
Hydralazine—Eosinophilia—Doxorubicin—pancreatic cancer	0.00141	0.00152	CcSEcCtD
Hydralazine—Palpitations—Docetaxel—pancreatic cancer	0.00141	0.00152	CcSEcCtD
Hydralazine—Weight decreased—Epirubicin—pancreatic cancer	0.00139	0.0015	CcSEcCtD
Hydralazine—Angina pectoris—Doxorubicin—pancreatic cancer	0.00139	0.0015	CcSEcCtD
Hydralazine—Hypersensitivity—Irinotecan—pancreatic cancer	0.00139	0.00149	CcSEcCtD
Hydralazine—Myalgia—Docetaxel—pancreatic cancer	0.00136	0.00146	CcSEcCtD
Hydralazine—Arthralgia—Docetaxel—pancreatic cancer	0.00136	0.00146	CcSEcCtD
Hydralazine—Nausea—Sunitinib—pancreatic cancer	0.00136	0.00146	CcSEcCtD
Hydralazine—Pancytopenia—Doxorubicin—pancreatic cancer	0.00135	0.00146	CcSEcCtD
Hydralazine—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.00135	0.00145	CcSEcCtD
Hydralazine—Jaundice—Epirubicin—pancreatic cancer	0.00134	0.00145	CcSEcCtD
Hydralazine—Conjunctivitis—Epirubicin—pancreatic cancer	0.00134	0.00144	CcSEcCtD
Hydralazine—Dysuria—Doxorubicin—pancreatic cancer	0.00133	0.00144	CcSEcCtD
Hydralazine—Neutropenia—Doxorubicin—pancreatic cancer	0.00133	0.00144	CcSEcCtD
Hydralazine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00133	0.00143	CcSEcCtD
Hydralazine—Haematuria—Epirubicin—pancreatic cancer	0.00131	0.00141	CcSEcCtD
Hydralazine—Oedema—Docetaxel—pancreatic cancer	0.0013	0.0014	CcSEcCtD
Hydralazine—Pruritus—Gemcitabine—pancreatic cancer	0.0013	0.0014	CcSEcCtD
Hydralazine—Weight decreased—Doxorubicin—pancreatic cancer	0.00129	0.00139	CcSEcCtD
Hydralazine—Diarrhoea—Irinotecan—pancreatic cancer	0.00129	0.00139	CcSEcCtD
Hydralazine—Agranulocytosis—Epirubicin—pancreatic cancer	0.00128	0.00138	CcSEcCtD
Hydralazine—Pruritus—Fluorouracil—pancreatic cancer	0.00127	0.00137	CcSEcCtD
Hydralazine—Thrombocytopenia—Docetaxel—pancreatic cancer	0.00127	0.00137	CcSEcCtD
Hydralazine—Tachycardia—Docetaxel—pancreatic cancer	0.00127	0.00137	CcSEcCtD
Hydralazine—Diarrhoea—Gemcitabine—pancreatic cancer	0.00125	0.00135	CcSEcCtD
Hydralazine—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.00125	0.00135	CcSEcCtD
Hydralazine—Dizziness—Irinotecan—pancreatic cancer	0.00124	0.00134	CcSEcCtD
Hydralazine—Jaundice—Doxorubicin—pancreatic cancer	0.00124	0.00134	CcSEcCtD
Hydralazine—Anorexia—Docetaxel—pancreatic cancer	0.00124	0.00134	CcSEcCtD
Hydralazine—Conjunctivitis—Doxorubicin—pancreatic cancer	0.00124	0.00133	CcSEcCtD
Hydralazine—Hepatitis—Epirubicin—pancreatic cancer	0.00123	0.00133	CcSEcCtD
Hydralazine—Diarrhoea—Fluorouracil—pancreatic cancer	0.00123	0.00133	CcSEcCtD
Hydralazine—Hypoaesthesia—Epirubicin—pancreatic cancer	0.00123	0.00132	CcSEcCtD
Hydralazine—Hypotension—Docetaxel—pancreatic cancer	0.00121	0.00131	CcSEcCtD
Hydralazine—Haematuria—Doxorubicin—pancreatic cancer	0.00121	0.00131	CcSEcCtD
Hydralazine—Vomiting—Irinotecan—pancreatic cancer	0.0012	0.00129	CcSEcCtD
Hydralazine—Dizziness—Fluorouracil—pancreatic cancer	0.00119	0.00128	CcSEcCtD
Hydralazine—Agranulocytosis—Doxorubicin—pancreatic cancer	0.00119	0.00128	CcSEcCtD
Hydralazine—Rash—Irinotecan—pancreatic cancer	0.00119	0.00128	CcSEcCtD
Hydralazine—Dermatitis—Irinotecan—pancreatic cancer	0.00118	0.00128	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.00118	0.00128	CcSEcCtD
Hydralazine—Headache—Irinotecan—pancreatic cancer	0.00118	0.00127	CcSEcCtD
Hydralazine—Paraesthesia—Docetaxel—pancreatic cancer	0.00117	0.00126	CcSEcCtD
Hydralazine—Vomiting—Gemcitabine—pancreatic cancer	0.00116	0.00126	CcSEcCtD
Hydralazine—Dyspnoea—Docetaxel—pancreatic cancer	0.00116	0.00125	CcSEcCtD
Hydralazine—Rash—Gemcitabine—pancreatic cancer	0.00115	0.00125	CcSEcCtD
Hydralazine—Dermatitis—Gemcitabine—pancreatic cancer	0.00115	0.00124	CcSEcCtD
Hydralazine—Headache—Gemcitabine—pancreatic cancer	0.00115	0.00124	CcSEcCtD
Hydralazine—Flushing—Epirubicin—pancreatic cancer	0.00115	0.00124	CcSEcCtD
Hydralazine—Vomiting—Fluorouracil—pancreatic cancer	0.00114	0.00124	CcSEcCtD
Hydralazine—Dyspepsia—Docetaxel—pancreatic cancer	0.00114	0.00123	CcSEcCtD
Hydralazine—Hepatitis—Doxorubicin—pancreatic cancer	0.00114	0.00123	CcSEcCtD
Hydralazine—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.00114	0.00123	CcSEcCtD
Hydralazine—Rash—Fluorouracil—pancreatic cancer	0.00114	0.00122	CcSEcCtD
Hydralazine—Dermatitis—Fluorouracil—pancreatic cancer	0.00113	0.00122	CcSEcCtD
Hydralazine—Decreased appetite—Docetaxel—pancreatic cancer	0.00113	0.00122	CcSEcCtD
Hydralazine—Headache—Fluorouracil—pancreatic cancer	0.00113	0.00122	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.00112	0.00121	CcSEcCtD
Hydralazine—Nausea—Irinotecan—pancreatic cancer	0.00112	0.0012	CcSEcCtD
Hydralazine—Constipation—Docetaxel—pancreatic cancer	0.00111	0.0012	CcSEcCtD
Hydralazine—Chills—Epirubicin—pancreatic cancer	0.00111	0.00119	CcSEcCtD
Hydralazine—Nausea—Gemcitabine—pancreatic cancer	0.00109	0.00117	CcSEcCtD
Hydralazine—Feeling abnormal—Docetaxel—pancreatic cancer	0.00107	0.00116	CcSEcCtD
Hydralazine—Nausea—Fluorouracil—pancreatic cancer	0.00107	0.00115	CcSEcCtD
Hydralazine—Flushing—Doxorubicin—pancreatic cancer	0.00106	0.00114	CcSEcCtD
Hydralazine—Muscle spasms—Epirubicin—pancreatic cancer	0.00103	0.00111	CcSEcCtD
Hydralazine—Body temperature increased—Docetaxel—pancreatic cancer	0.00103	0.00111	CcSEcCtD
Hydralazine—Chills—Doxorubicin—pancreatic cancer	0.00102	0.00111	CcSEcCtD
Hydralazine—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000997	0.00108	CcSEcCtD
Hydralazine—Anaemia—Epirubicin—pancreatic cancer	0.000993	0.00107	CcSEcCtD
Hydralazine—Agitation—Epirubicin—pancreatic cancer	0.000987	0.00106	CcSEcCtD
Hydralazine—Malaise—Epirubicin—pancreatic cancer	0.000969	0.00105	CcSEcCtD
Hydralazine—Leukopenia—Epirubicin—pancreatic cancer	0.000961	0.00104	CcSEcCtD
Hydralazine—Hypersensitivity—Docetaxel—pancreatic cancer	0.000958	0.00103	CcSEcCtD
Hydralazine—Muscle spasms—Doxorubicin—pancreatic cancer	0.000956	0.00103	CcSEcCtD
Hydralazine—Palpitations—Epirubicin—pancreatic cancer	0.000949	0.00102	CcSEcCtD
Hydralazine—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000922	0.000995	CcSEcCtD
Hydralazine—Pruritus—Docetaxel—pancreatic cancer	0.00092	0.000992	CcSEcCtD
Hydralazine—Anaemia—Doxorubicin—pancreatic cancer	0.000919	0.000991	CcSEcCtD
Hydralazine—Myalgia—Epirubicin—pancreatic cancer	0.000914	0.000987	CcSEcCtD
Hydralazine—Arthralgia—Epirubicin—pancreatic cancer	0.000914	0.000987	CcSEcCtD
Hydralazine—Agitation—Doxorubicin—pancreatic cancer	0.000913	0.000985	CcSEcCtD
Hydralazine—Anxiety—Epirubicin—pancreatic cancer	0.000911	0.000983	CcSEcCtD
Hydralazine—Discomfort—Epirubicin—pancreatic cancer	0.000904	0.000975	CcSEcCtD
Hydralazine—Malaise—Doxorubicin—pancreatic cancer	0.000896	0.000967	CcSEcCtD
Hydralazine—Leukopenia—Doxorubicin—pancreatic cancer	0.00089	0.00096	CcSEcCtD
Hydralazine—Diarrhoea—Docetaxel—pancreatic cancer	0.000889	0.000959	CcSEcCtD
Hydralazine—Palpitations—Doxorubicin—pancreatic cancer	0.000878	0.000948	CcSEcCtD
Hydralazine—Oedema—Epirubicin—pancreatic cancer	0.000877	0.000946	CcSEcCtD
Hydralazine—Dizziness—Docetaxel—pancreatic cancer	0.000859	0.000927	CcSEcCtD
Hydralazine—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000858	0.000926	CcSEcCtD
Hydralazine—Tachycardia—Epirubicin—pancreatic cancer	0.000856	0.000923	CcSEcCtD
Hydralazine—Arthralgia—Doxorubicin—pancreatic cancer	0.000846	0.000913	CcSEcCtD
Hydralazine—Myalgia—Doxorubicin—pancreatic cancer	0.000846	0.000913	CcSEcCtD
Hydralazine—Anxiety—Doxorubicin—pancreatic cancer	0.000843	0.00091	CcSEcCtD
Hydralazine—Discomfort—Doxorubicin—pancreatic cancer	0.000836	0.000902	CcSEcCtD
Hydralazine—Anorexia—Epirubicin—pancreatic cancer	0.000836	0.000902	CcSEcCtD
Hydralazine—Vomiting—Docetaxel—pancreatic cancer	0.000826	0.000892	CcSEcCtD
Hydralazine—Rash—Docetaxel—pancreatic cancer	0.000819	0.000884	CcSEcCtD
Hydralazine—Hypotension—Epirubicin—pancreatic cancer	0.000819	0.000884	CcSEcCtD
Hydralazine—Dermatitis—Docetaxel—pancreatic cancer	0.000819	0.000883	CcSEcCtD
Hydralazine—Headache—Docetaxel—pancreatic cancer	0.000814	0.000878	CcSEcCtD
Hydralazine—Oedema—Doxorubicin—pancreatic cancer	0.000811	0.000875	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000799	0.000862	CcSEcCtD
Hydralazine—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000794	0.000857	CcSEcCtD
Hydralazine—Tachycardia—Doxorubicin—pancreatic cancer	0.000792	0.000854	CcSEcCtD
Hydralazine—Paraesthesia—Epirubicin—pancreatic cancer	0.000787	0.000849	CcSEcCtD
Hydralazine—Dyspnoea—Epirubicin—pancreatic cancer	0.000782	0.000843	CcSEcCtD
Hydralazine—Anorexia—Doxorubicin—pancreatic cancer	0.000773	0.000834	CcSEcCtD
Hydralazine—Nausea—Docetaxel—pancreatic cancer	0.000772	0.000833	CcSEcCtD
Hydralazine—Dyspepsia—Epirubicin—pancreatic cancer	0.000772	0.000833	CcSEcCtD
Hydralazine—Decreased appetite—Epirubicin—pancreatic cancer	0.000762	0.000822	CcSEcCtD
Hydralazine—Hypotension—Doxorubicin—pancreatic cancer	0.000758	0.000818	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000757	0.000817	CcSEcCtD
Hydralazine—Constipation—Epirubicin—pancreatic cancer	0.00075	0.000809	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000739	0.000797	CcSEcCtD
Hydralazine—Paraesthesia—Doxorubicin—pancreatic cancer	0.000728	0.000786	CcSEcCtD
Hydralazine—Dyspnoea—Doxorubicin—pancreatic cancer	0.000723	0.00078	CcSEcCtD
Hydralazine—Feeling abnormal—Epirubicin—pancreatic cancer	0.000722	0.000779	CcSEcCtD
Hydralazine—Dyspepsia—Doxorubicin—pancreatic cancer	0.000714	0.00077	CcSEcCtD
Hydralazine—Decreased appetite—Doxorubicin—pancreatic cancer	0.000705	0.000761	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.0007	0.000756	CcSEcCtD
Hydralazine—Urticaria—Epirubicin—pancreatic cancer	0.000696	0.000751	CcSEcCtD
Hydralazine—Constipation—Doxorubicin—pancreatic cancer	0.000694	0.000748	CcSEcCtD
Hydralazine—Body temperature increased—Epirubicin—pancreatic cancer	0.000693	0.000748	CcSEcCtD
Hydralazine—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000668	0.000721	CcSEcCtD
Hydralazine—Hypersensitivity—Epirubicin—pancreatic cancer	0.000646	0.000697	CcSEcCtD
Hydralazine—Urticaria—Doxorubicin—pancreatic cancer	0.000644	0.000695	CcSEcCtD
Hydralazine—Body temperature increased—Doxorubicin—pancreatic cancer	0.000641	0.000692	CcSEcCtD
Hydralazine—Pruritus—Epirubicin—pancreatic cancer	0.00062	0.000669	CcSEcCtD
Hydralazine—Diarrhoea—Epirubicin—pancreatic cancer	0.0006	0.000647	CcSEcCtD
Hydralazine—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000598	0.000645	CcSEcCtD
Hydralazine—Dizziness—Epirubicin—pancreatic cancer	0.00058	0.000625	CcSEcCtD
Hydralazine—Pruritus—Doxorubicin—pancreatic cancer	0.000574	0.000619	CcSEcCtD
Hydralazine—Vomiting—Epirubicin—pancreatic cancer	0.000557	0.000601	CcSEcCtD
Hydralazine—Diarrhoea—Doxorubicin—pancreatic cancer	0.000555	0.000599	CcSEcCtD
Hydralazine—Rash—Epirubicin—pancreatic cancer	0.000553	0.000596	CcSEcCtD
Hydralazine—Dermatitis—Epirubicin—pancreatic cancer	0.000552	0.000596	CcSEcCtD
Hydralazine—Headache—Epirubicin—pancreatic cancer	0.000549	0.000593	CcSEcCtD
Hydralazine—Dizziness—Doxorubicin—pancreatic cancer	0.000536	0.000579	CcSEcCtD
Hydralazine—Nausea—Epirubicin—pancreatic cancer	0.000521	0.000562	CcSEcCtD
Hydralazine—Vomiting—Doxorubicin—pancreatic cancer	0.000516	0.000556	CcSEcCtD
Hydralazine—Rash—Doxorubicin—pancreatic cancer	0.000511	0.000552	CcSEcCtD
Hydralazine—Dermatitis—Doxorubicin—pancreatic cancer	0.000511	0.000551	CcSEcCtD
Hydralazine—Headache—Doxorubicin—pancreatic cancer	0.000508	0.000548	CcSEcCtD
Hydralazine—Nausea—Doxorubicin—pancreatic cancer	0.000482	0.00052	CcSEcCtD
